Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.

Clicks: 261
ID: 103143
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.
Reference Key
choy2020remdesivirantiviral Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Choy, Ka-Tim;Yin-Lam Wong, Alvina;Kaewpreedee, Prathanporn;Sia, Sin-Fun;Chen, Dongdong;Yan Hui, Kenrie Pui;Wing Chu, Daniel Ka;Wai Chan, Michael Chi;Pak-Hang Cheung, Peter;Huang, Xuhui;Peiris, Malik;Yen, Hui-Ling;
Journal Antiviral research
Year 2020
DOI S0166-3542(20)30200-X
URL
Keywords
abstract covid-19 remdesivir emetine homoharringtonine lopinavir ritonavir

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.